Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?

被引：11

作者：

Samos, Matej ^{[1
]}

Fedor, Marian ^{[2
]}

Kovar, Frantisek ^{[1
]}

Duraj, Lukas ^{[2
]}

Stanciakova, Lucia ^{[2
]}

Galajda, Peter ^{[1
]}

Stasko, Jan ^{[2
]}

Kubisz, Peter ^{[2
]}

Mokan, Marian ^{[1
]}

机构：

[1] Comenius Univ, Jessenius Fac Med Martin, Dept Internal Med 1, Kollarova 2, Martin 03659, Slovakia

[2] Comenius Univ, Jessenius Fac Med Martin, Dept Hematol & Blood Transfus, Natl Ctr Hemostasis & Thrombosis, Martin 03659, Slovakia

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2016年 / 27卷 / 02期

关键词：

high on-treatment platelet reactivity; percutaneous coronary intervention; stent thrombosis; ticagrelor; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; PRASUGREL; PRETREATMENT; EFFICACY; IMPACT;

D O I：

10.1097/MBC.0000000000000406

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Stent thrombosis is a morbid complication following percutaneous coronary intervention (PCI). Dual antiplatelet therapy significantly reduces stent thrombosis risk. However, the antiplatelet response to clopidogrel - the most frequently used ADP receptor antagonist in post-PCI patients - varies among individuals. High on-treatment platelet reactivity was repeatedly associated with the risk of stent thrombosis. Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel. This agent offers a unique mechanism of action, no relevant pharmacological interactions, consistent platelet inhibition, and a good safety profile. This article reviews the prospective use of ticagrelor in the treatment of stent thrombosis in acute coronary syndrome patients undergoing PCI of culprit coronary lesion. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：117 / 120

页数：4